We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cigna (CI) Hits 52-Week High on Recent Buyout, Growth Plans
Read MoreHide Full Article
On Jul 12, the stock of Cigna Corp. (CI - Free Report) hit a 52-week high of $173.44. The rise in the stock is believed to have been driven by an acquisition, its detailed long-term growth plans unveiled at a recent investor conference and the lifting of Medicare Advantage (MA) sanctions from the Centers for Medicare & Medicaid Services (CMS).
In the last one year, the stock has returned 32%, a tad lower than the Zacks categorized Insurance - Multi line industry’s gain of 33% but significantly higher than the return of 12% from the S&P 500 index.
Investors favorably viewed Cigna’s recent purchase of Zurich Insurance Middle East, which will provide it a stronger foothold in the Gulf countries of UAE, Lebanon, Kuwait and Oman. The deal will further strengthen its already strong international business, the premium at which has witnessed a 12% CAGR to $1.9 billion in 2016 from $0.9 billion in 2009.
This deal has made the company’s investors quite optimism about its efforts to diversify operations outside U.S. markets that are faced with stiff competition and stringent regulations.
Shares of the company have performed strongly despite the failed merger of Cigna with Anthem Inc. . Cigna’s investors gained confidence in its ability to grow as a stand-alone entity, after it shared detailed long-term growth plans at an investor conference on Jun 21.
The company gave 2021 earnings per share (EPS) guidance of $16, and an EPS annual growth guidance of 10-13%. The 2021 EPS guidance took into consideration substantial balance sheet strength of $7 billion to $14 billion deployable cash.
Segment wise, long-term revenue growth guidance was – mid-teens for Global Supplemental; high-single digit for MA, high-single digit for the Commercial Employer market and mid-single digit for Group Disability and Life. Management reiterated that the company will execute on at least $2 billion of the authorized $3.7 billion in share repurchase in 2017.
Investors also acknowledge the company’s ability to maintain the medical cost trend at a level below the industry average. The company has been able to achieve this on the back of its value-based care initiatives.
Shares must also have received a boost from the lifting of MA sanctions (last month) by CMS. The company was restricted to sell MA plans since Jan 2016, after it was found guilty of violating regulations relating to these.
Now, with the sanctions lifted, Cigna will be able to participate in an open enrollment period for 2018 plans, which will start from Nov 1, 2017. The development will add to the company’s organic growth by increasing MA membership.
Aetna beat estimates in each of the last four quarters, with an average positive surprise of 8.62%.
Humana beat estimates in each of the last four quarters, with an average positive surprise of 3.75%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Cigna (CI) Hits 52-Week High on Recent Buyout, Growth Plans
On Jul 12, the stock of Cigna Corp. (CI - Free Report) hit a 52-week high of $173.44. The rise in the stock is believed to have been driven by an acquisition, its detailed long-term growth plans unveiled at a recent investor conference and the lifting of Medicare Advantage (MA) sanctions from the Centers for Medicare & Medicaid Services (CMS).
In the last one year, the stock has returned 32%, a tad lower than the Zacks categorized Insurance - Multi line industry’s gain of 33% but significantly higher than the return of 12% from the S&P 500 index.
Investors favorably viewed Cigna’s recent purchase of Zurich Insurance Middle East, which will provide it a stronger foothold in the Gulf countries of UAE, Lebanon, Kuwait and Oman. The deal will further strengthen its already strong international business, the premium at which has witnessed a 12% CAGR to $1.9 billion in 2016 from $0.9 billion in 2009.
This deal has made the company’s investors quite optimism about its efforts to diversify operations outside U.S. markets that are faced with stiff competition and stringent regulations.
Shares of the company have performed strongly despite the failed merger of Cigna with Anthem Inc. . Cigna’s investors gained confidence in its ability to grow as a stand-alone entity, after it shared detailed long-term growth plans at an investor conference on Jun 21.
The company gave 2021 earnings per share (EPS) guidance of $16, and an EPS annual growth guidance of 10-13%. The 2021 EPS guidance took into consideration substantial balance sheet strength of $7 billion to $14 billion deployable cash.
Segment wise, long-term revenue growth guidance was – mid-teens for Global Supplemental; high-single digit for MA, high-single digit for the Commercial Employer market and mid-single digit for Group Disability and Life. Management reiterated that the company will execute on at least $2 billion of the authorized $3.7 billion in share repurchase in 2017.
Investors also acknowledge the company’s ability to maintain the medical cost trend at a level below the industry average. The company has been able to achieve this on the back of its value-based care initiatives.
Shares must also have received a boost from the lifting of MA sanctions (last month) by CMS. The company was restricted to sell MA plans since Jan 2016, after it was found guilty of violating regulations relating to these.
Now, with the sanctions lifted, Cigna will be able to participate in an open enrollment period for 2018 plans, which will start from Nov 1, 2017. The development will add to the company’s organic growth by increasing MA membership.
Cigna carries a Zacks Rank #2 (Buy). Other companies in the health insurance space with the same Zacks Rank are Aetna Inc. and Humana Inc. (HUM - Free Report) . You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Aetna beat estimates in each of the last four quarters, with an average positive surprise of 8.62%.
Humana beat estimates in each of the last four quarters, with an average positive surprise of 3.75%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>